HDSA Convention Registration, Clinical Trial Strategy, HDF Webinar Series

Registration for the 38th Annual HDSA Convention is now open!  

Join us in New Orleans, Louisiana, from June 1-3 for the 38th Annual HDSA Convention! To reserve your spot today or learn more about Convention scholarships, click here. Convention will feature lots of research programming, including a showcase of currently recruiting clinical trials, an opportunity to ask HD scientists questions, talks from HDSA-funded researchers, and more. We hope to see you there! 

Annexon strategy for Phase 2/3 trial for ANX005 

Annexon announced last year that it will initiate a Phase 2/3 trial of ANX005 for treatment of HD. A recent article covered comments about the trial design made during the J.P. Morgan Healthcare Conference this month. ANX005 is an antibody administered via IV with the goal of preserving synapses, the connections between brain cells. It does this by blocking a part of the immune system that becomes overactive in HD, known as the classical complement pathway. Different people have different levels of activity in their classical complement pathways.  In the Phase 2 trial for the drug, Annexon found that participants with higher complement activity at the start of the trial saw greater benefit from the drug. The new Phase 2/3 trial will look to confirm this, while also exploring potential benefit for people with lower complement activity. They have designed two-pronged trial approaches like this in the past. To read more, click here.  

HDF 2023 Researcher Spotlight webinar series  

Next month, the Hereditary Disease Foundation will kick off their research spotlight webinar series highlighting scientists studying HD and other brain disorders. The series will kick off on February 9th at 12 PM ET with a presentation from Steven Finkenbeiner, MD, PhD, on how technological innovation is transforming HD research. To register for this webinar, click here. To check out the rest of HDF’s upcoming presenters in 2023, click here.